A 2035 Clinical Research Vision and Roadmap for High‐Risk Neuroblastoma

ABSTRACT Despite the introduction of anti‐GD2 antibody therapy, outcomes for children with high‐risk neuroblastoma remain poor, with low cure rates and a high proportion of survivors facing long‐term sequelae. In this report, leaders from international cooperative groups and patient advocacy organizations review lessons learnt, identify current challenges, and provide a vision to bring new agents into frontline therapy to increase cure rates and reduce long‐term toxicities over the next decade. The implementation of this vision requires improved global collaboration, incorporation of novel biomarkers, and a strengthened interaction with the regulatory landscape.